Health Canada Approves Advanced Viral Research Corp.'s Application for Clinical IND

YONKERS, N.Y.--(BUSINESS WIRE)--Advanced Viral Research Corp. (OTCBB: ADVR), a research based biopharmaceutical company dedicated to anti-cancer drug discovery and development, announced today that a Clinical Trial Application for the use of AVR118 in cancer patients has been approved by the Therapeutic Products Division of Health Canada. This approval will allow the company to commence clinical trials in patients with histologically confirmed malignancies who present with clinically demonstrable anorexia or anorexia-cachexia syndrome.